Imcivree

Generic name: Setmelanotide
Dosage form: injection, for subcutaneous use
Drug class: Melanocortin receptor agonists

Usage of Imcivree

Imcivree is a prescription medicine used in adults and children 6 years of age and older with obesity due to:

The genetic conditions proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, to help them lose weight and keep the weight off.

Bardet-Biedl syndrome (BBS) to help them lose weight and keep the weight off.

Your healthcare provider should order a genetic test to cOnfirm POMC, PCSK1, or LEPR deficiency before you start treatment.

Imcivree is not for use in people with the following conditions because it may not work:

Obesity due to suspected POMC, PCSK1, or LEPR deficiency not confirmed by genetic testing or with benign or likely benign testing results.

Other types of obesity not related to POMC, PCSK1, or LEPR deficiency, or BBS, including obesity associated with other genetic conditions and general obesity.

It is not known if this medicine is safe and effective in children under 6 years of age.

Imcivree side effects

Imcivree may cause serious side effects, including:

Male and female sexual function problems. Imcivree can cause an erection that happens without any sexual activity in males (spontaneous penile erection) and unwanted sexual reactions (changes in sexual arousal that happen without any sexual activity) in females. If you have an erection lasting longer than 4 hours, get emergency medical help right away.

Depression and suicidal thoughts or actions. You or a caregiver should call your healthcare provider right away if you have any new or worsening symptoms of depression.

Increased skin pigmentation and darkening of skin lesions (moles or nevi) you already have. These changes happen because of how Imcivree works in the body and will go away when you stop using Imcivree. You should have a full body skin exam before starting and during treatment to check for skin changes.

Benzyl Alcohol toxicity. Benzyl alcohol is a preservative in Imcivree. Benzyl alcohol can cause serious side effects, including death, in premature and low-birth weight infants, who have received medicines that contain benzyl alcohol. Imcivree should not be used in premature and low-birth weight infants.

The most common side effects of include:

injection site reactions

darkening of the skin

nausea

vomiting

headache

erection that happens without any sexual activity in males

diarrhea

stomach pain.

These are not all the possible side effects.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or Rhythm Pharmaceuticals at 1-833-789-6337.

Before taking Imcivree

Before you start treatment, tell your healthcare provider about all your medical conditions, including if you:

have or have had areas of darkened skin, including skin discoloration (hyperpigmentation).

have or have had depression, or suicidal thoughts or behavior.

have kidney problems.

are pregnant or planning to become pregnant. Losing weight while pregnant may harm your unborn baby. Your healthcare provider may stop your treatment if you become pregnant. Tell your healthcare provider if you become pregnant or think you might be pregnant during treatment.

are breastfeeding or plan to breastfeed. It is not known if Imcivree passes into your breastmilk. You should not breastfeed during treatment.

Relate drugs

How to use Imcivree

Usual Adult Dose for Obesity:

Initial dose: 2 mg suBC UTAneously once a day for 2 weeks -If tolerated and additional weight loss is desired: Increase to 3 mg subcutaneously once a day -If not tolerated: Reduce to 1 mg subcutaneously once a day; if additional weight loss is desired, titrate to 2 mg subcutaneously once a day Maintenance dose: 1 to 3 mg per day Maximum dose: 3 mg per day Comments: -To assess tolerability, monitor for gastrointestinal adverse reactions. -Evaluate weight loss after 12 to 16 weeks of treatment in patients with POMC-, PCSK1-, or LEPR-deficiency or after 1 year in patients with BBS; if patient has not lost at least 5% of baseline body weight, it is unlikely they will achieve and sustain clinically meaningful weight loss with continued treatment. -Available tests for the detection of POMC, PCSK1, or LEPR variants have not been approved or cleared by the FDA. -This drug is not for the treatment of patients with obesity due to suspected POMC, PCKS1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign or other types of obesity unrelated to POMC, PCSK1, or LEPR deficiency, or BBS, including obesity associated with other genetic syndromes and general (polygenic) obesity as it is not expected to be effective. Use: For chronic weight management in patients with obesity due to proopiomelanocortin (POMC), proprotein convertase/subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance; and Bardet-Biedl syndrome (BBS).

Usual Pediatric Dose for Obesity:

6 to less than 12 years: Initial dose: 1 mg subcutaneously once a day for 2 weeks -If tolerated and additional weight loss is desired: Increase to 2 mg subcutaneously once a day -If not tolerated: Reduce to 0.5 mg subcutaneously once a day; if additional weight loss is desired, titrate to 3 mg subcutaneously once a day Maintenance dose: 0.5 to 3 mg per day Maximum dose: 3 mg per day 12 years or older: Initial dose: 2 mg subcutaneously once a day for 2 weeks -If tolerated and additional weight loss is desired: Increase to 3 mg subcutaneously once a day -If not tolerated: Reduce to 1 mg subcutaneously once a day; if additional weight loss is desired, titrate to 2 mg subcutaneously once a day Maintenance dose: 1 to 3 mg per day Maximum dose: 3 mg per day Comments: -To assess tolerability, monitor for gastrointestinal adverse reactions. -Evaluate weight loss after 12 to 16 weeks of treatment in patients with POMC-, PCSK1-, or LEPR-deficiency or after 1 year in patients with BBS; if patient has not lost at least 5% of baseline body weight (or 5% of baseline BMI for patients with continued growth potential) it is unlikely they will achieve and sustain clinically meaningful weight loss with continued treatment. -Available tests for the detection of POMC, PCSK1, or LEPR variants have not been approved or cleared by the FDA. -This drug is not for the treatment of patients with obesity due to suspected POMC, PCKS1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign or other types of obesity unrelated to POMC, PCSK1, or LEPR deficiency, or BBS, including obesity associated with other genetic syndromes and general (polygenic) obesity as it is not expected to be effective. Use: For chronic weight management in patients 6 years or older with obesity due to proopiomelanocortin (POMC), proprotein convertase/subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance; and Bardet-Biedl syndrome (BBS).

What other drugs will affect Imcivree

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Imcivree has low potential for drug interactions.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.